Novel Therapeutic for Rheumatoid Arthritis
Unique ScFv/antibody highly specific for disease-modified collagen II (found in arthritis patients) has been used to facilitate targeted delivery of therapy to arthritic joints. A fusion construct with mTNFR2-Fc (mouse version of Etanercept) significantly increased efficacy over mTNFR2-Fc alone (p<0.001). Another construct with using viral IL-10 (novel MoA) also provided significant reduction in disease (p=0.0048). MHRA meeting is scheduled for April.
Antibody/Peptide to Integrin Alpha-v β6
Uniquely generated ScFvs and peptides, structurally-guided to increase binding efficacy. Alpha-v β6 integrin is an epithelial- restricted transmembrane cell surface receptor highly associated with tumours. In animal models studies radio-labelled antibody localised to avb6 tumour. Candidate ScFv & peptides inhibit tumour adhesion, ScFv/peptide internalises selectively into avβ6 positive cells and thus are suitable for ADC programmes.
Anti-Angiogenic Peptide (QM107)
QM107 exploits a novel pathway (not VEGF). QM107 has shown to cause an 80% reduction in sprouting in murine aortic ring model, a 35% decrease in HUVEC cell migration and micro-capillary formation and a 50% decrease in angiogenesis in Matrigel plug assays. PK data excellent.
Therapeutic for Alzheimer’s disease
Metal protein attenuating compounds (MPACs) for treating neurological diseases associated with beta amyloid protein aggregation. We have the first proof that a novel small molecule has cognition- modifying properties in a transgenic animal model of Alzheimer's disease at 20 mg/kg oral dosing over a three month period. The compound also decreased early amyloid beta cellular load by 18% in the cortex and increased by 42% the synaptophysin (synaptic marker) content in a second transgenic animal model of Alzheimer’s disease, thus indicating that the compound interferes with early amyloid aggregation and has clear neuroprotective and neurotrophic effects.
Biomarkers for Endometriosis
A unique panel of auto-antibody and miRNA biomarkers as a novel non-invasive diagnostic or therapeutic targets for endometriosis (up to 90% sensitivity and 87% selectivity). Importantly it can distinguish between endometriosis and other forms of intra-abdominal inflammation.
Novel Disposable Fistula Probes and Seton for Anal Fistula Surgery
The new approach involves the use of disposable probes with setons in surgery for an improved patient outcome of the treatment of anal fistulas that develop as result of anorectal abcesses.
Non-invasive device to treat abnormal heart rhythm
A small, disposable, non-invasive (class II) handheld device into which you blow to generate a significant amount of pressure in the chest to treat patients with abnormal heart rhythms.
Currently no such device exists, this device will deliver a significantly improved method of treatment and diagnosis of abnormal heart rhythms in comparison to the conventional techniques.
New in vitro Hepatocyte–Based Drug Screen for Anti-Hepatitis C Drugs
This assay provides phenotypic screening designed to assess patient responsiveness prior to therapy. Pre -existing viral resistance can be identified to spare patients suffering side effects and save costs associated with failed therapies
Advanced Cell Migration Assays Using Micro-Patterned and Dynamically Adhesive Surfaces
A novel cell migration assay in which interactions between cells and their surrounding microenvironment can be precisely controlled to study processes such as wound healing, neurite extension, angiogenesis and metastasis.
Type 1 diabetes early diagnostic biomarker
Novel auto-antibody, patent about to be filed, simple Elisa assay, 79% sensitivity 97% specificity, 266 patient sample study (T1D 116; T2D 82; HC 68).
Pancreatic ductal adenocarcinoma
Biomarkers for the early detection (stage I-II) of PDAC via serum or urine. 80% sensitivity, 77% specificity.
Coloured fluorescent Antibody
A stable recombinant antibody with intrinsic red fluorescent properties for qualitative and quantitative immunofluorescence analysis. Genetically assembled rather than covalently linked incorporating the fluorophore as a bridging scaffold confers superior properties. Expression and purification steps can be monitored without the need for sophisticated detection equipment. The platform allows panels of coloured antibodies to generate both diagnostic and therapeutic molecules.
Protection from Multiple Organ Failure in Trauma-Haemorrhage Patients
Trauma induced organ failure is the leading cause of death in the under 40s. A commonly used, but as yet never submitted for regulatory approval, anti-infection molecule, has demonstrated a significant reduction in multiple organ failure indicators (renal, kidney and cerebral) in non-clinical studies. Fully funded Phase IIa trauma organ failure study is planned for Q3-2015. Other indications AKI, stroke available for partnering/investment.
Highly Sensitive and Specific Diagnostic Marker for Rheumatoid Arthritis
A 326 patient sample analysis from three key European centres has identified a novel auto-antibody to modified type II collagen as an early diagnostic for rheumatoid arthritis.90% sensitivity and 100% specificity for early RA regardless of ACPA status.
Antibody for Synovial Microvasculature in Rheumatoid Arthritis
A novel ScFv antibody, ScFv A7, highly specific for human arthritic synovial microvasculature has been generated. Fixed tissue samples with a bi-specific antibody (ScFv A7 + ScFv anti‐TNFα) have demonstrated the targeting capabilities, and cellular assays have demonstrated maintenance of anti‐TNFα activity.
Calcitonin and Glucocorticoid Combination Therapy for Chronic Inflammatory Disorders
Non-clinical models of arthritis have shown using glucocorticoid in combination with calcitonin allows for a 4-fold reduction glucocorticoid dose without loss of therapeutic effect whilst reducing side effects markedly.
Diagnostic Marker of Aggressive Cancer in 'Low Risk' Prostate Cancer Patients
A 700+ patient retrospective study with up to 20 years of follow-up data has identified methylation of 3 genes to be an important biomarker (p<0.005) of aggressive prostate cancers that would regarded as low risk by current standards (PSA and Gleason Score).
For further information about opportunities in BioPharma, please contact:
Dr Michele Hill-Perkins
Tel. +44 (0)207 882 5581